ACTIV4a

Official account of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Acute Inpatient Anti-Thrombotic Study (ACTIV-4a)

[Dr. Jeffrey Berger @PlateletDoc]

>95% confidence in futility in non-critically #Covid_19 - @ACTIV4a still enrolling P2Y12 in critically ill patients - generating data at warp speed thanks to @NIHFunding @nih_nhlbi

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#AHA21 #LBCT
P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A
🩸thrombosis/inflam in #COVID
🩸RCT of P2Yy12, non-critical pt: 562 pts
🩸Stopped for futility; 40% women; Ticag used in 63%
🩸 No benefit of P2Yy12 in non-critical pts
@AHAMeetings

[Stephen Lapinsky @StephenLap]

Superb @UofT_DoM Grand Rounds by @ecgoligher & @PatrickLawlerMD on the background, statistical approach & interpretation of the adaptive Bayesian design multiplatform @ATTACC_COVID / @ACTIV4a / @remap_cap anticoag in COVID trial.

https://t.co/zKUKxENPQD
https://t.co/5FQLNzXLaO

[NEJM @NEJM]

In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. https://t.co/3JzKdmL3SB #IDTwitter

[Anthony Gordon @agordonICU]

Great international collaboration @remap_cap @ATTACC_COVID @ACTIV4a

[Matthew D. Neal, MD @macky_neal]

The incredible efforts of so many have led to the publication of both #mpRCT papers reporting results of anticoagulation in #COVID19. @NEJM @ATTACC_COVID @remap_cap @ACTIV4a Most challenging/rewarding effort of my career https://t.co/gaw7AdMdLH https://t.co/BLrAUOjIay

[ATTACC CAP @ATTACC_CAP]

Results of our therapeutic anticoagulation mpRCT with @ACTIV4a and @remap_cap is being live-streamed below.

Results have now been published in the @NEJM

Moderate state: https://t.co/M2SiIMmIc1
Critically ill: https://t.co/y1JibxHyLj
Editorial: https://t.co/YgWAD1qYbM

[Ryan Zarychanski @RZarychanski]

The final presentation timed with a public report. Come find out how the trial was done & what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19. @ATTACC_COVID @remap_cap @ACTIV4a @UM_RadyFHS @UHN @CCCTG_ @canvector @ASH_hematology @JustinTrudeau

[Critical Care Reviews @CritCareReviews]

Big night tomorrow night!
Free livestream from 20:30 UTC
https://t.co/sGWuTjv0BC

Supported by @MyIntensiveCare

[Critical Care Reviews @CritCareReviews]

@RZarychanski @SCCM @ASH_hematology @UM_RadyFHS @CCCTG_ @ThrombosisCan @INVENT_VTE Looking forward to discussing these results next week. This will impact COVID-19 practice worldwide 🌐
@ATTACC_COVID @remap_cap @ACTIV4a @charlot_summers @ecgoligher @PatrickLawlerMD

[remap-cap @remap_cap]

For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8

[Ryan Zarychanski @RZarychanski]

Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support.
https://t.co/TkhGs5qow5

[Dr. Jeffrey Berger @PlateletDoc]

Just had our @ACTIV4a v1.1 protocol review - we hope to start randomizing to yes/no P2Y12i in hospitalized #COVID19 very soon!!@macky_neal @LucyKornblith @ATTACC_COVID @MaryCushmanMD @PatrickLawlerMD @statberry

[Professor Beverley Hunt OBE (also on BlueSky) @bhwords]

In this free access @bmj_latest editorial we discuss
- the changing views & practice of thromboprophylaxis in hospitalised patients with COVI-19 through the pandemic
- the recent RCT interim evidence from @remap_cap @ATTACC_COVID & @ACTIV4a as to what is the best dose of LMWH

[Dr. Jeffrey Berger @PlateletDoc]

@ToddNeale @connors_md @Erik_Klok_MD Was nice discussing thrombosis and antithrombotic Rx in #covid19 from the mpRCT between @ACTIV4a @ATTACC_COVID @remap_cap

[Ewan Goligher @ecgoligher]

@ATTACC_COVID A brief thread on interpreting organ support-free days as an endpoint for RCTs including @ATTACC_COVID @remap_cap @ACTIV4a

Visit the simulator linked here to explore how the endpoint is influenced by its various components

https://t.co/ZwyJcdC0uk

[ACTIV4a @ACTIV4a]

We are releasing the interim (final data coming and publication submission pending) data from our amazing mpRCT collaboration w/ @ATTACC_COVID @remap_cap to aid in clinician decision making on anticoagulants for #COVID19: https://t.co/Tg78vM5xfD @nih_nhlbi @macky_neal

[University of Pittsburgh @PittTweet]

Early results of a worldwide trial, coordinated in part by researchers at Pitt, found that full doses of heparin, a blood thinner, were not only safe but also reduced the need for vital organ support, such as ventilation for COVID-19 patients.

More here: https://t.co/90tqRDqkSX

[Lucy Zumwinkle Kornblith, MD, FACS @LucyKornblith]

@ACTIV4a @AaronKornblith @UCSFchipper @UCSF_BCHSI @UCSFHospitals @UCSFSurgery I’d say that the real forces of nature are @ACTIV4a @remap_cap @ATTACC_COVID and their tireless, dedicated, brilliant, amazing leadership. Grateful for the opportunity to learn from and work alongside all of you.

[ACTIV4a @ACTIV4a]

@AaronKornblith @LucyKornblith @UCSFchipper @UCSF_BCHSI @UCSFHospitals @UCSFSurgery Indeed congrats to @LucyKornblith. She is a force of nature. We could not have done it without her and the Multi-Net team #surgeonscientist